Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2007

Noven Receives $5.9M in ADHD Patch Partnership with Shire

  • Noven Pharmaceuticals reported that Shire has exercised its option to acquire the exclusive development rights to a transdermal patch for ADHD. Noven thus received a $5.9-million milestone payment.

    Noven successfully completed a Phase I study of an amphetamine transdermal system (ATS) for the treatment of ADHD. Shire has requested modifications to the original patch formulation to align ATS, and Noven will be compensated for its continuing development efforts.

    "Noven and Shire have worked collaboratively since 2003 to develop and commercialize patches for ADHD, with Daytrana representing the first patch approved in the category," remarks Jeffrey F. Eisenberg, Noven's senior vp, strategic alliances. "We are very pleased to see this alliance expanded to include a Noven patch expected to be aligned with Shire's ADHD portfolio."

    Shire is the global licensee of Daytrana, a methylphenidate transdermal system for the treatment of ADHD. The drug was developed and manufactured by Noven and launched by Shire in June, 2006. It reportedly is currently the only transdermal product approved for ADHD therapy.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »